22157.jpg
Global Crohn's Disease Forecast and Market Analysis Report 2020-2027 - Despite Formulary Constraints, Novel Pipeline Drugs will Expand the Market
12 janv. 2021 07h03 HE | Research and Markets
Dublin, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The "Crohn's Disease Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering. As specialty products, therapies...
Lyfebulb and UnitedHealth Group Announce Winners of the 2018 Innovation Challenge for Patient Entrepreneurs
26 juil. 2018 09h00 HE | Lyfebulb
MINNETONKA, Minn. and NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Lyfebulb LLC and UnitedHealth Group (NYSE:UNH) have selected Jon Margalit of Complete Start as the winner of the first-ever Lyfebulb...
Lyfebulb and UnitedHealth Group Announce 11 Finalists for Their 2018 Innovation Challenge for Patient Entrepreneurs
28 juin 2018 09h00 HE | Lyfebulb
Challenge recognizes companies whose founders have been affected by inflammatory bowel disease Winners to receive monetary prizes for creative and effective solutions to address IBD MINNETONKA,...
Lyfebulb and UnitedHealth Group Announce an Innovation Challenge for Patient Entrepreneurs with Inflammatory Bowel Disease
23 avr. 2018 15h18 HE | Lyfebulb; UnitedHealth Group
MINNETONKA, Minn. and NEW YORK, April 23, 2018 (GLOBE NEWSWIRE) -- Lyfebulb LLC and UnitedHealth Group (NYSE:UNH) invite patient entrepreneurs to compete in “Empowering Patients: An Innovation...
Photo Release -- Top Global Experts Join AXIM Biotechnologies Advisory Board
06 nov. 2014 09h00 HE | AXIM BIOTECHNOLOGIES, INC
NEW YORK, Nov. 6, 2014 (GLOBE NEWSWIRE) -- AXIM Biotechnologies (OTC:AXIM) is setting the "green standard" in the industrial hemp industry, tapping two world-renown experts to advise on the Company's...
Qu Biologics Begins Research with McMaster University to Study New Crohn's Disease Research Model
03 déc. 2013 10h00 HE | Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 3, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to stimulate the...
Video Release -- Help Yourself While Helping Others: The Personal Benefits of Taking Steps for Crohn's Disease and Ulcerative Colitis
25 juil. 2013 13h48 HE | Crohn's and Colitis Foundation of America
NEW YORK, July 25, 2013 (GLOBE NEWSWIRE) -- Known collectively as inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis affects 1 in 200 people.  Whether you, or someone you...
Qu Biologics Enrolls First Patient in Phase 1/2 Clinical Trial of QBECO SSI for the Treatment of Crohn's Disease
11 juin 2013 16h22 HE | Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 11, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the...